Literature DB >> 23070272

[Carcinoma of the esophagus, esophagogastric junction, and stomach. Cooperation between pathology and surgery].

A H Hölscher1, U K Fetzner.   

Abstract

Cooperation between pathology and surgery plays a decisive role in the treatment of carcinoma of the esophagus, esophagogastric junction, and stomach. Preoperatively, the carcinoma is confirmed and the histologic type, grading, type of extension (stomach) and immunohistochemical or molecular-biological parameters, if necessary, are determined. For exclusion or diagnosis of distant metastases, peritoneal carcinosis, or secondary tumors, further biopsies or cytological examinations may be required. All results contribute to the individualized treatment. In case of endoscopic treatment, the completeness of resection of the carcinoma and the depth of infiltration must be identified with extraordinary diligence. Postoperative proof of tumor, location, histological type, completeness of resection and safety margin have to be identified. Detailed T-status, N-status with declaration of the ratio of affected and nonaffected number of lymph nodes, location of affected lymph nodes, extracapsular lymph node spread, invasion of lymphatic and vascular vessels and perineural sheets are important parameters. The description of tumor regression after neoadjuvant treatment (histomorphological response) is of special interest.

Entities:  

Mesh:

Year:  2012        PMID: 23070272     DOI: 10.1007/s00292-012-1680-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  15 in total

1.  Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus.

Authors:  Ralf Metzger; Uta Drebber; Stephan E Baldus; Stefan P Mönig; Arnulf H Hölscher; Elfriede Bollschweiler
Journal:  Ann Surg Oncol       Date:  2008-11-27       Impact factor: 5.344

2.  [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].

Authors:  M Moehler; S-E Al-Batran; T Andus; M Anthuber; J Arends; D Arnold; D Aust; P Baier; G Baretton; J Bernhardt; H Boeing; E Böhle; C Bokemeyer; J Bornschein; W Budach; E Burmester; K Caca; W A Diemer; C F Dietrich; M Ebert; A Eickhoff; C Ell; J Fahlke; H Feussner; R Fietkau; W Fischbach; W Fleig; M Flentje; H E Gabbert; P R Galle; M Geissler; I Gockel; U Graeven; L Grenacher; S Gross; J T Hartmann; M Heike; V Heinemann; B Herbst; T Herrmann; S Höcht; R D Hofheinz; H Höfler; T Höhler; A H Hölscher; M Horneber; J Hübner; J R Izbicki; R Jakobs; C Jenssen; S Kanzler; M Keller; R Kiesslich; G Klautke; J Körber; B J Krause; C Kuhn; F Kullmann; H Lang; H Link; F Lordick; K Ludwig; M Lutz; R Mahlberg; P Malfertheiner; S Merkel; H Messmann; H-J Meyer; S Mönig; P Piso; S Pistorius; R Porschen; T Rabenstein; P Reichardt; K Ridwelski; C Röcken; I Roetzer; P Rohr; W Schepp; P M Schlag; R M Schmid; H Schmidberger; W-H Schmiegel; H-J Schmoll; G Schuch; C Schuhmacher; K Schütte; W Schwenk; M Selgrad; A Sendler; J Seraphin; T Seufferlein; M Stahl; H Stein; C Stoll; M Stuschke; A Tannapfel; R Tholen; P Thuss-Patience; K Treml; U Vanhoefer; M Vieth; H Vogelsang; D Wagner; U Wedding; A Weimann; H Wilke; C Wittekind
Journal:  Z Gastroenterol       Date:  2011-04-07       Impact factor: 2.000

3.  Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer.

Authors:  Arnulf H Hölscher; Elfriede Bollschweiler; Wolfgang Schröder; Ralf Metzger; Christian Gutschow; Uta Drebber
Journal:  Ann Surg       Date:  2011-11       Impact factor: 12.969

4.  MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Authors:  Jochen K Lennerz; Eunice L Kwak; Allison Ackerman; Michael Michael; Stephen B Fox; Kristin Bergethon; Gregory Y Lauwers; James G Christensen; Keith D Wilner; Daniel A Haber; Ravi Salgia; Yung-Jue Bang; Jeffrey W Clark; Benjamin J Solomon; A John Iafrate
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

5.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

6.  Transthoracic esophagectomy after endoscopic mucosal resection in patients with early esophageal carcinoma.

Authors:  W Schröder; K Wirths; C Gutschow; D Vallböhmer; M Bludau; B Schumacher; H Neuhaus; A H Hölscher
Journal:  J Gastrointest Surg       Date:  2008-10-16       Impact factor: 3.452

7.  Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes.

Authors:  Christian G Peyre; Jeffrey A Hagen; Steven R DeMeester; Jan J B Van Lanschot; Arnulf Hölscher; Simon Law; Alberto Ruol; Ermanno Ancona; S Michael Griffin; Nasser K Altorki; Thomas W Rice; John Wong; Toni Lerut; Tom R DeMeester
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

Review 8.  [GERD and complications: when is surgery necessary?].

Authors:  A H Hölscher; E Bollschweiler; C Gutschow
Journal:  Z Gastroenterol       Date:  2007-11       Impact factor: 2.000

9.  Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.

Authors:  E Bollschweiler; R Metzger; U Drebber; S Baldus; D Vallböhmer; M Kocher; A H Hölscher
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

Review 10.  Reporting of short-term clinical outcomes after esophagectomy: a systematic review.

Authors:  Natalie S Blencowe; Sean Strong; Angus G K McNair; Sara T Brookes; Tom Crosby; S Michael Griffin; Jane M Blazeby
Journal:  Ann Surg       Date:  2012-04       Impact factor: 12.969

View more
  1 in total

Review 1.  [Pathology of the R1 classification in visceral cancer surgery].

Authors:  M J Pollheimer; C Langner
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.